The Real Question: Which Probiotics Work for What?
The term "probiotics" covers thousands of different bacterial and yeast strains, each with distinct effects. Asking "do probiotics work?" is like asking "do medications work?" — the answer depends entirely on which specific strain you are taking and what outcome you expect.
The strongest clinical evidence supports specific strains for specific conditions. Marketing claims about general "gut health" from unspecified probiotic blends are far less supported.
Strains With Strong Clinical Evidence
Lactobacillus rhamnosus GG (LGG)
LGG is the single most studied probiotic strain in the world, with over 300 published clinical trials. Its strongest evidence is for:
Antibiotic-associated diarrhea (AAD): A 2012 Cochrane meta-analysis of 82 randomized controlled trials found that probiotics (predominantly LGG and S. boulardii) reduced the risk of AAD by 42%. LGG specifically has been shown to reduce AAD incidence in children and adults when started within 48 hours of antibiotic initiation.
Acute infectious diarrhea: Multiple RCTs demonstrate that LGG reduces the duration of acute gastroenteritis by approximately 1 day in children and adults.
Dose: 10-20 billion CFU daily
Saccharomyces boulardii
S. boulardii is a beneficial yeast (not a bacterium) that is naturally resistant to antibiotics, making it uniquely suitable for use during antibiotic treatment.
C. difficile infection prevention: A 2017 meta-analysis in the Journal of Clinical Gastroenterology found that S. boulardii reduced the risk of C. difficile-associated diarrhea by 53% when given alongside antibiotics.
Traveler's diarrhea: Several RCTs support S. boulardii for preventing traveler's diarrhea when started 5 days before travel and continued throughout the trip.
Dose: 250-500mg (typically 5-10 billion CFU) daily
Bifidobacterium lactis (BB-12 and HN019)
BB-12 is one of the most extensively documented probiotic strains for immune function and general wellness.
Immune support: A 2011 RCT published in the British Journal of Nutrition found that BB-12 supplementation increased antibody responses to influenza vaccination and reduced the incidence of respiratory infections in elderly subjects.
Regularity: The HN019 strain has demonstrated significant improvements in gastrointestinal transit time and relief from constipation in multiple clinical trials.
Dose: 1-10 billion CFU daily
What the Evidence Does NOT Support
Generic "gut health" claims: Products marketed for vague "digestive wellness" or "microbiome balance" without specifying strains or citing clinical evidence for those strains are not well-supported.
Extremely high CFU counts as a selling point: There is no evidence that 100 billion CFU is more effective than 10 billion CFU for most applications. Efficacy depends on strain specificity, not quantity.
Permanent microbiome colonization: Most supplemental probiotics are transient — they pass through the GI tract and do not permanently colonize the gut. Benefits typically require ongoing supplementation. The exception is after antibiotic disruption, where probiotics may help beneficial native species recover faster.
Next-Generation Probiotics
Emerging research is moving beyond traditional Lactobacillus and Bifidobacterium strains toward next-generation probiotics:
Akkermansia muciniphila: A keystone gut bacterium associated with metabolic health, healthy body weight, and gut barrier integrity. A 2019 landmark RCT in Nature Medicine by Depommier et al. found that pasteurized Akkermansia supplementation improved insulin sensitivity, reduced cholesterol, and decreased body weight in overweight adults. This was the first human clinical trial demonstrating benefits of this species.
Tributyrin (butyrate prodrugs): While not a probiotic per se, tributyrin supplements deliver butyrate — a short-chain fatty acid produced by healthy gut bacteria — directly to the colon. Butyrate is the primary fuel for colonocytes (colon cells) and supports gut barrier integrity, reduces intestinal inflammation, and promotes regulatory T-cell development.
How to Choose a Quality Probiotic
Strain specificity: The label should list specific strains (e.g., Lactobacillus rhamnosus GG), not just species names. Benefits are strain-specific.
CFU guarantee at expiration: The label should state the CFU count at expiration date, not at time of manufacture. Probiotic viability decreases over time, and products guaranteeing counts only at manufacture may deliver far fewer live organisms by the time you take them.
Storage requirements: Some strains require refrigeration; others are shelf-stable. Check the label and buy from retailers that handle the product correctly.
Third-party testing: Independent verification of strain identity, viability, and absence of contaminants provides additional confidence.
Clinical evidence for the specific strains included: The strongest products contain strains with published clinical trials — not just species that sound similar to studied strains.
Common Probiotic Mistakes
| Mistake | Why It Matters | Better Approach |
|---|---|---|
| Choosing by highest CFU count | More is not better; strain specificity matters | Match strain to your specific goal |
| Taking during antibiotics without timing | Antibiotics can kill probiotic bacteria | Take probiotics 2-3 hours after each antibiotic dose |
| Stopping after one week | Most benefits require 2-4 weeks minimum | Continue for at least 4-8 weeks to assess |
| Expecting permanent effects | Most strains are transient, not colonizing | Plan for ongoing supplementation |
| Ignoring prebiotic fiber | Probiotics need fuel to thrive | Include prebiotic fiber (inulin, GOS) in your diet |
Who Benefits Most From Probiotics
During and after antibiotics: This is the strongest use case. Start probiotics within 48 hours of beginning antibiotics and continue for 2-4 weeks after completing the course.
Frequent travelers: S. boulardii has specific evidence for preventing traveler's diarrhea.
Immune support for elderly adults: BB-12 and LGG have evidence for reducing respiratory infections and improving vaccine responses in older adults.
IBS (certain subtypes): Some evidence supports specific strains for IBS-D (diarrhea-predominant), though results are mixed and strain-dependent.